Follow The Filings

Opaleye Management Inc. James Silverman

Boston, MA 23 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $1.1B
  • 58 holdings
  • 2026 Q2
  • +45.5% QoQ
  • Top 5 46.8%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 58 holdings

Top 5 46.8%, top 10 64.8%

  1. LQDA, Liquidia 17.7%
  2. ETON, Eton Pharmaceuticals 9.4%
  3. HROW, Harrow 9.2%
  4. IRON, Disc Medicine 5.7%
  5. URGN, Urogen 4.8%
  6. APGE, Apogee Therapeutics 4.7%
  7. MGTX, Meiragtx 4.3%
  8. SLGL, Sol-Gel Technologies 3.3%
  9. RZLT, Rezolute 3.0%
  10. TGTX, TG Therapeutics 2.7%
  11. IMMX, Immix Biopharma 2.2%
  12. CBIO, Crescent Biopharma 2.1%
  13. Other 30.9%

AUM over time

2026 Q2 $1.1B +45.5% QoQ
2021 Q3: $535M 2021 Q3: $535M
Q3 2021
2021 Q4: $471M, −12.0% QoQ 2021 Q4: $471M, −12.0% QoQ
Q4
2022 Q1: $322M, −31.6% QoQ 2022 Q1: $322M, −31.6% QoQ
Q1 2022
2022 Q2: $222M, −31.1% QoQ 2022 Q2: $222M, −31.1% QoQ
Q2
2022 Q3: $242M, +9.0% QoQ 2022 Q3: $242M, +9.0% QoQ
Q3
2022 Q4: $288M, +19.0% QoQ 2022 Q4: $288M, +19.0% QoQ
Q4
2023 Q1: $334M, +16.0% QoQ 2023 Q1: $334M, +16.0% QoQ
Q1 2023
2023 Q2: $418M, +25.1% QoQ 2023 Q2: $418M, +25.1% QoQ
Q2
2023 Q3: $307M, −26.6% QoQ 2023 Q3: $307M, −26.6% QoQ
Q3
2023 Q4: $376M, +22.5% QoQ 2023 Q4: $376M, +22.5% QoQ
Q4
2024 Q1: $437M, +16.2% QoQ 2024 Q1: $437M, +16.2% QoQ
Q1 2024
2024 Q2: $438M, +0.2% QoQ 2024 Q2: $438M, +0.2% QoQ
Q2
2024 Q3: $600M, +37.0% QoQ 2024 Q3: $600M, +37.0% QoQ
Q3
2024 Q4: $571M, −4.8% QoQ 2024 Q4: $571M, −4.8% QoQ
Q4
2025 Q1: $449M, −21.4% QoQ 2025 Q1: $449M, −21.4% QoQ
Q1 2025
2025 Q2: $499M, +11.1% QoQ 2025 Q2: $499M, +11.1% QoQ
Q2
2025 Q3: $707M, +41.7% QoQ 2025 Q3: $707M, +41.7% QoQ
Q3
2025 Q4: $758M, +7.2% QoQ 2025 Q4: $758M, +7.2% QoQ
Q4
2026 Q1: $759M, +0.1% QoQ 2026 Q1: $759M, +0.1% QoQ
Q1 2026
2026 Q2: $1.1B, +45.5% QoQ 2026 Q2: $1.1B, +45.5% QoQ
Q2

Book

2024 Q3 2024 Q2, filed 14 Nov, long equity only

Download CSV Download Excel All activity
HROW, Harrow Health 29.92% Hold 3,990,000 $44.96 $179M — —
TGTX, TG Therapeutics 8.89% Hold 2,280,000 $23.39 $53M — —
OCUL, Ocular Therapeutix 7.29%, was 8.29% Reduce −5.3% 5,025,000 $8.70 $44M −282,500 +$7.4M
ARVN, Arvinas 5.16%, was 3.38% Add +126.1% 1,255,000 $24.63 $31M +700,000 +$16M
CDXS, Codexis 4.51%, was 2.45% Add +153.8% 8,770,000 $3.08 $27M +5,315,000 +$16M
RYTM, Rhythm Pharmaceuticals 4.37%, was 4.83% Reduce −2.9% 500,000 $52.39 $26M −15,000 +$5M
Keros Therapeutics 3.83% Add +7.6% 395,276 $58.07 $23M +27,776 +$6.2M
Immunome 3.02% Add +12.2% 1,237,500 $14.62 $18M +135,000 +$4.8M
LQDA, Liquidia 2.83%, was 0.89% Add +422.5% 1,698,142 $10.00 $17M +1,373,142 +$13M
ETON, Eton Pharmaceuticals 2.78%, was 1.80% Add +16.1% 2,780,000 $6.00 $17M +385,000 +$8.8M
EWTX, Edgewise Therapeutics 2.33%, was 2.39% Reduce −9.9% 522,500 $26.69 $14M −57,500 +$3.5M
Cargo Therapeutics 1.97%, was 2.08% Reduce −2.6% 541,437 $21.86 $12M −14,263 +$2.7M
APLT, Applied Therapeutics Inc' 1.87% Reduce −21.4% 1,320,000 $8.50 $11M −360,000 +$3.4M
PCVX, Vaxcyte 1.62% Hold 85,000 $114.27 $9.7M — —
NRIX, Nurix Therapeutics 1.57% Add +0.3% 420,000 $22.47 $9.4M +1,072 +$694K
Acelyrin 1.56% Add +19.9% 1,893,660 $4.93 $9.3M +313,660 +$2.4M
TRVI, Trevi Therapeutics 1.43%, was 1.80% Reduce −2.9% 2,567,990 $3.34 $8.6M −77,010 +$695K
Biodesix 1.16%, was 1.41% Reduce −5.1% 3,815,000 $1.83 $7M −205,000 +$820K
DNA, Ginkgo Bioworks 1.11% New 820,202 $8.15 $6.7M +820,202 +$6.7M
Jasper Therapeutics 1.11%, was 2.03% Reduce −9.8% 353,500 $18.81 $6.6M −38,500 −$2.2M
XOMA 1.10% Hold 250,000 $26.48 $6.6M — —
NUVL, Nuvalent 1.09%, was 1.03% Add +7.9% 64,000 $102.30 $6.5M +4,700 +$2M
NAMS 0.93% Add +6.3% 335,000 $16.60 $5.6M +20,000 −$490K
URGN, Urogen 0.86%, was 1.58% Reduce −1.9% 404,100 $12.70 $5.1M −7,900 −$1.8M
PTGX, Protagonist Therapeutics 0.79% Hold 105,000 $45.00 $4.7M — —
CYTK, Cytokinetics 0.66%, was 2.46% Reduce −62.1% 75,300 $52.80 $4M −123,200 −$6.8M
Gossamer Bio 0.62%, was 0.80% Reduce −6.3% 3,665,010 $1.01 $3.7M −244,990 +$183K
ZNTL, Zentalis Pharmaceuticals 0.59% New 967,000 $3.68 $3.6M +967,000 +$3.6M
Protara Therapeutics 0.51%, was 1.21% Reduce −27.0% 1,681,154 $1.83 $3.1M −623,108 −$2.2M
RZLT, Rezolute 0.38% New 466,563 $4.85 $2.3M +466,563 +$2.3M
Catalyst Pharmaceuticals 0.37%, was 2.27% Reduce −82.4% 112,500 $19.88 $2.2M −527,500 −$7.7M
ABCL, Abcellera Biologics 0.35%, was 0.14% Add +300.0% 800,000 $2.60 $2.1M +600,000 +$1.5M
Lyell Immunopharma 0.32%, was 0.55% Reduce −16.5% 1,395,000 $1.38 $1.9M −275,000 −$496K
Allakos 0.26%, was 0.64% Reduce −13.4% 2,407,600 $0.6532 $1.6M −372,400 −$1.2M
RLMD, Relmada Therapeutics 0.26%, was 0.41% Reduce −20.0% 480,000 $3.24 $1.6M −120,000 −$245K
PEPG, Pepgen 0.26% New 179,200 $8.55 $1.5M +179,200 +$1.5M
Revance Therapeutics 0.24% New 275,000 $5.19 $1.4M +275,000 +$1.4M
Syros Pharmaceuticals 0.23%, was 1.02% Reduce −24.3% 654,943 $2.15 $1.4M −210,500 −$3.1M
Aerovate Therapeutics 0.15% Hold 440,000 $2.09 $920K — —
Regulus Therapeutics 0.14%, was 0.60% Reduce −63.7% 535,000 $1.57 $840K −940,000 −$1.8M
IBIO 0.14% Hold 375,000 $2.22 $833K — —
ADGM, Adagio Medical 0.05% New 110,571 $2.58 $285K +110,571 +$285K

Exits / last held

Gone since 2024 Q2, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
FDMT, 4D Molecular Therapeutics 1.66% Exit 0 $20.99 $7.3M −345,750 −$7.3M
IOVA, Iovance Biotherapeutics 1.64% Exit 0 $8.02 $7.2M −897,000 −$7.2M
INTC, Intellia Therapeutics 1.11% Exit 0 $22.38 $4.9M −218,000 −$4.9M
Lexicon Pharmaceuticals 0.72% Exit 0 $1.68 $3.2M −1,875,000 −$3.2M
Savara 0.66% Exit 0 $4.03 $2.9M −714,960 −$2.9M
Ventyx Biosciences 0.63% Exit 0 $2.31 $2.7M −1,190,000 −$2.7M
VSTM, Verastem 0.62% Exit 0 $2.98 $2.7M −915,000 −$2.7M
FULC, Fulcrum Therapeutics 0.40% Exit 0 $6.20 $1.8M −285,000 −$1.8M
Karyopharm Therapeutics 0.28% Exit 0 $0.8674 $1.2M −1,425,000 −$1.2M
PMV Pharmaceuticals 0.18% Exit 0 $1.62 $770K −475,000 −$770K
DSGN, Design Therapeutics 0.16% Exit 0 $3.35 $687K −205,000 −$687K
Aligos Therapeutics 0.10% Exit 0 $0.3500 $441K −1,260,000 −$441K
Reneo Pharmaceuticals 0.06% Exit 0 $1.51 $249K −165,000 −$249K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2024 Q2. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 58 $1.1B +45.5% 13F-HR 8/14/2026 000142050626001803
2026 Q1 54 $759M +0.1% 13F-HR 5/15/2026 000142050626001151
2025 Q4 54 $758M — RESTATEMENT 4/13/2026 000149315226016299
2025 Q4 54 $758M +7.2% 13F-HR 2/17/2026 000149315226007085
2025 Q3 43 $707M +41.7% 13F-HR 11/14/2025 000149315225023429
2025 Q2 41 $494M — RESTATEMENT 8/15/2025 000164117225024301
2025 Q2 41 $499M +11.1% 13F-HR 8/14/2025 000164117225023977
2025 Q1 45 $449M −21.4% 13F-HR 5/15/2025 000164117225010914
2024 Q4 39 $571M −4.8% 13F-HR 2/14/2025 000149315225006852
2024 Q3 44 $600M +37.0% 13F-HR 11/14/2024 000149315224045811
2024 Q2 51 $438M +0.2% 13F-HR 8/14/2024 000149315224032150
2024 Q1 52 $459M — RESTATEMENT 5/29/2024 000149315224021780
2024 Q1 51 $437M +16.2% 13F-HR 5/15/2024 000149315224019869
2023 Q4 47 $376M +22.5% 13F-HR 2/14/2024 000149315224006653
2023 Q3 41 $307M −26.6% 13F-HR 11/15/2023 000149315223041364
2023 Q2 47 $418M +25.1% 13F-HR 8/14/2023 000149315223028636
2023 Q1 41 $334M +16.0% 13F-HR 5/15/2023 000149315223016769
2022 Q4 40 $288M +19.0% 13F-HR 2/10/2023 000149315223004277
2022 Q3 42 $242M +9.0% 13F-HR 11/14/2022 000149315222032068
2022 Q2 47 $222M −31.1% 13F-HR 8/15/2022 000149315222022856
2022 Q1 45 $322M −31.6% 13F-HR 5/16/2022 000149315222013764
2021 Q4 39 $471M −12.0% 13F-HR 2/14/2022 000149315222004434
2021 Q3 48 $535M — 13F-HR 11/16/2021 000149315221028799

About

Opaleye Management Inc.

23 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Opaleye Management Inc.
Notable person
James Silverman
Location
Boston, MA
All SEC filings
View on sec.gov